94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Björn Samans1,2
Marta Rosselló Chornet3Araceli Rosselló Chornet1Janine Jung1Konstantin Schildknecht1Laura Lozza1Lourdes Alos Zaragoza3
Javier Hernández Laforet3
Nina Babel4
Sven Olek1*- 1Ivana Türbachova Laboratory for Epigenetics, Epiontis, Precision for Medicine GmbH, Berlin, Germany
- 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
- 3Department of Anesthesiology and Resuscitation, Consortium General University Hospital of Valencia, Valencia, Spain
- 4Center for Translational Medicine, Medical Clinic 1, Marien Hospital Herne, University Hospitals of the Ruhr-University of Bochum, Herne, Germany
A Corrigendum on
Epigenetic immune monitoring for COVID-19 disease course prognosis
by Samans B, Rosselló Chornet M, Rosselló Chornet A, Jung J, Schildknecht K, Lozza L, Alos Zaragoza L, Hernández Laforet J, Babel N, Olek S. Front Immunol. doi: 10.3389/fimmu.2023.1107900
In the published article, there was an error regarding the affiliations for Björn Samans. As well as having affiliation 1, they should also have affiliation “Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, SARS-CoV-2, epigenetic qPCR, immune monitoring, lymphopenia, disease prognosis
Citation: Samans B, Rosselló Chornet M, Rosselló Chornet A, Jung J, Schildknecht K, Lozza L, Alos Zaragoza L, Hernández Laforet J, Babel N and Olek S (2024) Corrigendum: Epigenetic immune monitoring for COVID-19 disease course prognosis. Front. Immunol. 15:1451571. doi: 10.3389/fimmu.2024.1451571
Received: 19 June 2024; Accepted: 20 June 2024;
Published: 27 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Samans, Rosselló Chornet, Rosselló Chornet, Jung, Schildknecht, Lozza, Alos Zaragoza, Hernández Laforet, Babel and Olek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sven Olek, c3Zlbi5vbGVrQHByZWNpc2lvbmZvcm1lZGljaW5lLmNvbQ==